← Leaderboards
Joel I. Ward
La Biomed Res Inst/ Harbor Ucla Med Ctr
$1,938,369
Attributed
$1,938,369
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $422.2K · FY2005–10$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$1,938,369 · 11
By mechanism
M01$1,095,338 · 9
U54$843,031 · 1
N01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelVaccinesResourcesPreventionClinical ResearchGenital HerpesPreventHepatitis A VaccinesHerpesvirus 1, HumanGrantClinical TrialsAge-YearsInstitutionParticipantCommunitiesHepatitis AEfficacy TrialDouble-Blind MethodEnrollmentComputer Retrieval Of Information On Scientific Projects DatabaseCollegeFundingAluminum SulfateDose
Grant awards (15)
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLACT$9,214
M01 · FY2010 · RR · contact PI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLACT$29,785
M01 · FY2009 · RR · contact PI
Vaccines and Diagnostics Trials$218,546
U54 · FY2008 · AI · contact PI
CLINICAL TRIAL: A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS$49,706
M01 · FY2008 · RR · contact PI
Vaccines and Diagnostics Trials$214,096
U54 · FY2007 · AI · contact PI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLACT$34,202
M01 · FY2007 · RR · contact PI
Vaccines and Diagnostics Trials$215,813
U54 · FY2006 · AI · contact PI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLACT$112,819
M01 · FY2006 · RR · contact PI
PILOT STUDY TO OPTIMIZE AND STANDARDIZE UMBILICAL CORD BLOOD COLLECTION AND T$374
M01 · FY2006 · RR · contact PI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLACT$223,183
M01 · FY2005 · RR
Vaccines and Diagnostics Trials$194,576
U54 · FY2005 · AI
PILOT STUDY TO OPTIMIZE AND STANDARDIZE UMBILICAL CORD BLOOD COLLECTION AND T$4,445
M01 · FY2005 · RR
Multicenter, Double-Blind, Randomized, Dose-Response Stu$575,766
M01 · FY2004 · RR
A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylact.$55,844
M01 · FY2004 · RR
EVALUATING NON-AIDS INFECTIOUS DISEASE CONTROL MEASURES$0
N01 · FY2000 · AI